{
    "clinical_study": {
        "@rank": "90971", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Combining more than one drug may kill more tumor cells. It is\n      not yet known if paclitaxel plus carboplatin is more effective with or without topotecan for\n      ovarian epithelial cancer.\n\n      PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel plus\n      carboplatin with or without topotecan in treating patients who have stage IIB, stage III, or\n      stage IV ovarian epithelial cancer."
        }, 
        "brief_title": "Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer", 
        "condition": [
            "Fallopian Tube Cancer", 
            "Ovarian Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Ovarian Neoplasms", 
                "Fallopian Tube Neoplasms", 
                "Neoplasms, Glandular and Epithelial"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Compare survival of patients with stage IIB, III, or IV ovarian epithelial\n      carcinoma after receiving treatment with paclitaxel and carboplatin with or without\n      topotecan. II. Compare progression-free survival of these patients after receiving these\n      treatment regimens. III. Compare the response rate and response duration in these patients\n      treated with these regimens. IV. Determine the toxic effects of the combination of\n      paclitaxel, carboplatin, and topotecan in these patients. V. Compare the toxic effects of\n      these treatment regimens in these patients. VI. Compare quality of life of these patients\n      treated with these regimens.\n\n      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to\n      participating center and stage (stage IIB and stage III optimally debulked to no greater\n      than 1 cm residual tumor vs stage IV regardless of residual tumor or residual tumor greater\n      than 1 cm). Patients are randomized to one of two treatment arms. Arm I: Patients receive\n      paclitaxel IV over 3 hours and carboplatin IV over 0.5-1 hour on day 1 and topotecan IV over\n      0.5 hour on days 1-5. Treatment repeats every 21 days for 6 courses (topotecan is\n      administered for 4 courses only). Arm II: Patients receive paclitaxel and carboplatin as in\n      arm I. Treatment repeats every 21 days for 6 courses. Quality of life is assessed before\n      courses 1, 3, and 5 and at 3 weeks and 3 months after completion of treatment in both\n      treatment arms; before courses 1 and 3 of topotecan in arm I; and at 6 months after\n      completion of treatment in arm II. Patients are followed every 3 months for 2 years, every 6\n      months for 3 years, and then annually thereafter.\n\n      PROJECTED ACCRUAL: A total of 914 patients (457 per treatment arm) will be accrued for this\n      study over 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically confirmed stage IIB, III, or IV ovarian epithelial\n        carcinoma, fallopian tube, or extraovarian papillary serous carcinoma extending to the\n        ovary No mixed epithelial/non-epithelial tumors (e.g., mixed Mullerian tumors) No tumors\n        of low malignant potential (e.g., borderline tumors) No symptomatic brain metastases\n\n        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 OR Karnofsky\n        70-100% Life expectancy: More than 12 weeks Hematopoietic: Absolute neutrophil count at\n        least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5\n        times the upper limit of normal (ULN) Alkaline phosphatase no greater than 3 times ULN\n        Renal: Creatinine no greater than 1.25 times ULN Estimated glomerular filtration rate at\n        least 60 mL/min Cardiovascular: No history of congestive heart failure (even if medically\n        controlled) No New York Heart Association class III or IV heart disease No myocardial\n        infarction within the past 6 months No history of atrial or ventricular arrhythmias Other:\n        No motor or sensory neurologic pathology or symptoms greater than grade 1 No active\n        infection or other serious medical condition that would preclude study No prior allergy to\n        drug containing Cremophor EL No dementia or significantly altered mental state that would\n        preclude informed consent No complete bowel obstruction No other prior malignancy except\n        curatively treated nonmelanomatous skin cancer or carcinoma in situ of the cervix Not\n        pregnant or nursing Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy No concurrent WBC\n        transfusions Chemotherapy: No prior chemotherapy No other concurrent chemotherapy\n        Endocrine therapy: No concurrent hormonal therapy Radiotherapy: No prior radiotherapy No\n        concurrent radiotherapy Surgery: No more than 6 weeks since prior definitive laparotomy\n        and recovered Other: No other concurrent antineoplastic agents No other concurrent\n        investigational drugs"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 6, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00006454", 
            "org_study_id": "CDR0000067994", 
            "secondary_id": [
                "AGOSG-OVAR-7", 
                "NCI-V00-1602"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "topotecan hydrochloride", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carboplatin", 
                "Paclitaxel", 
                "Topotecan"
            ]
        }, 
        "keyword": [
            "stage II ovarian epithelial cancer", 
            "stage III ovarian epithelial cancer", 
            "stage IV ovarian epithelial cancer", 
            "fallopian tube cancer"
        ], 
        "lastchanged_date": "August 17, 2010", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/AGOSG-OVAR-7"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "D-10117"
                    }, 
                    "name": "Universitaetsklinikum Charite"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany", 
                        "zip": "D-53105"
                    }, 
                    "name": "Universitaetskliniken Bonn"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bremen", 
                        "country": "Germany", 
                        "zip": "D-28205"
                    }, 
                    "name": "Zentralkrankenhaus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "D-01307"
                    }, 
                    "name": "Medizinische Klinik I"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duesseldorf", 
                        "country": "Germany", 
                        "zip": "D-40225"
                    }, 
                    "name": "Universitaetsklinik Duesseldorf"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dusseldorf", 
                        "country": "Germany", 
                        "zip": "DOH-4-0217"
                    }, 
                    "name": "Evangelisches Krankenhaus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "zip": "D-60590"
                    }, 
                    "name": "Klinikum der J.W. Goethe Universitaet"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "zip": "DOH-6-5929"
                    }, 
                    "name": "Stadtische Kliniken Frankfurt-Hochst"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gottingen", 
                        "country": "Germany", 
                        "zip": "D-37075"
                    }, 
                    "name": "Universitaetsklinik Goettingen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greifswald", 
                        "country": "Germany", 
                        "zip": "D-17487"
                    }, 
                    "name": "Klinik Fuer Innere Medizin Hematology/Oncology, Ernst Moritz Armdt Universitaet"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany", 
                        "zip": "30659"
                    }, 
                    "name": "Frauenklinik der MHH"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Karlsruhe", 
                        "country": "Germany", 
                        "zip": "D-76137"
                    }, 
                    "name": "Vincentius Krankenhaus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kiel", 
                        "country": "Germany", 
                        "zip": "D-24105"
                    }, 
                    "name": "Christian-Albrechts University of Kiel"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Magdeburg", 
                        "country": "Germany", 
                        "zip": "39108"
                    }, 
                    "name": "Klinik der Otto-v.-Guericke-Universitat"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muenster", 
                        "country": "Germany", 
                        "zip": "D-48129"
                    }, 
                    "name": "Klinik und Poliklinik fuer Kinderheilkunde"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "zip": "D-81377"
                    }, 
                    "name": "Klinikum Grosshadern"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "zip": "D-81675"
                    }, 
                    "name": "Klinikum Rechts Der Isar/Technische Universitaet Muenchen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tuebingen", 
                        "country": "Germany", 
                        "zip": "D-72076"
                    }, 
                    "name": "Universitaetsklinikum Tuebingen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wiesbaden", 
                        "country": "Germany", 
                        "zip": "D-65199"
                    }, 
                    "name": "Dr. Horst-Schmidt-Kliniken"
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "official_title": "Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan", 
        "overall_official": {
            "affiliation": "University of Schleswig-Holstein", 
            "last_name": "Jacobus Pfisterer, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "reference": {
            "PMID": "20694564", 
            "citation": "Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, Pujade-Lauraine E, du Bois A; for the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support Care Cancer. 2010 Aug 6; [Epub ahead of print]"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00006454"
        }, 
        "results_reference": [
            {
                "PMID": "16882940", 
                "citation": "Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stahle A, Jackisch C, Hardy-Bessard AC, Mobus V, Quaas J, Richter B, Schroder W, Geay JF, Luck HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006 Aug 2;98(15):1036-45."
            }, 
            {
                "citation": "Pfisterer J, Lortholary A, Kimmig R, et al.: Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TC-Top) in first-line treatment of ovarian cancer FIGO stages IIb - IV. Interim results of a gynecologic cancer intergroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1793, 446, 2003."
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AGO Study Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 1999", 
        "study_design": "Allocation: Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2010"
    }, 
    "geocoordinates": {
        "Christian-Albrechts University of Kiel": "54.323 10.123", 
        "Dr. Horst-Schmidt-Kliniken": "50.063 8.243", 
        "Evangelisches Krankenhaus": "51.221 6.81", 
        "Frauenklinik der MHH": "52.384 9.727", 
        "Klinik Fuer Innere Medizin Hematology/Oncology, Ernst Moritz Armdt Universitaet": "54.087 13.392", 
        "Klinik der Otto-v.-Guericke-Universitat": "52.131 11.629", 
        "Klinik und Poliklinik fuer Kinderheilkunde": "51.951 7.626", 
        "Klinikum Grosshadern": "48.145 11.558", 
        "Klinikum Rechts Der Isar/Technische Universitaet Muenchen": "48.145 11.558", 
        "Klinikum der J.W. Goethe Universitaet": "50.111 8.682", 
        "Medizinische Klinik I": "51.031 13.757", 
        "Stadtische Kliniken Frankfurt-Hochst": "50.111 8.682", 
        "Universitaetsklinik Duesseldorf": "51.221 6.81", 
        "Universitaetsklinik Goettingen": "51.538 9.93", 
        "Universitaetskliniken Bonn": "50.712 7.105", 
        "Universitaetsklinikum Charite": "52.524 13.406", 
        "Universitaetsklinikum Tuebingen": "48.521 9.059", 
        "Vincentius Krankenhaus": "49.009 8.38", 
        "Zentralkrankenhaus": "53.085 8.821"
    }
}